IMPROVEMENT OF POSSIBILITIES OF TREATING PNEUMONIAS IN PATIENTS ON THE BACKGROUND OF ACUTE MYELOBLAST LEUCOSIS IN THE ASPECT OF IMMUNORESISTANCE MECHANISMS

Inna Borisova

Abstract


Aim: to analyze the influence of the immunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) on indices of cellular and humoral immunity in patients with pneumonias on the background of acute myeloblast leucosis to form new approaches to the improvement of treating pneumonias in patients with immunity disorders.

Materials and methods. The research group - 37 patients with pneumonia on the background of acute myeloblast leucosis, who underwent the program treatment on the base of the hematological center “MI city multi-profile clinical hospital №4” Dnipro city, 2014-2015. The age of patients from 23 to 45 years old; 10 women and 27 men. The diagnosis of leucosis and pneumonia forms was verified corresponding to modern conventional clinical and morphological criteria. Patients from the main research group (n = 18) were prescribed with glutamyl-cysteinyl-glycine disodium by the scheme 2 ml of 3 % (60 mg) i/v № 10 in mornings, summary dose - 300 mg. Indications of immunograms were studied: Т-lymphocytes, В-lymphocytes and their subpopulation composition (CD3 +, CD4 +, CD8 +, CD19 +, CD19-, CD16 +, CD56+) using the flowing laser cytofluorimetry. Immunoglobulin levels were determined by the method of immunoturbometry. Indications of immunograms were assessed in the treatment dynamics. The statistical processing – using packages of applied programs «Excel» and «Statistic 10».

Results. According to the analysis of indices of the cellular and humoral immunity of patients with pneumonia on the background of acute myeloblast leucosis, the process of glutamyl-cysteinyl-glycine disodium use proved the statistically reliable activation of phagocytosis and anti-infectious defense indices. The dynamics of humoral immunity indices also proved the positive influence on the state of the immune reactivity of the organism with the reliable increase of ІgА and Іg М, responsible for neutralization of infectious agents and bacterial toxins.

Conclusions: The use of the ummunomodeling preparation glutamyl-cysteinyl-glycine disodium (glutoxim) in patients with pneumonia on the background of acute myeloblast leucosis results in the improvement of indices of cellular and humoral immunity and phagocytosis activation. The research results prove the possibility of optimization of approaches to treating pneumonias in patients with severe immunity disorders by using immunomedeling therapy by glutamyl-cysteinyl-glycine disodium (glutoxim). 


Keywords


pneumonia; myeloblast leucosis; glutamyl-cysteinyl-glycine disodium; cellular and humoral immunity indices

Full Text:

PDF

References


Helfond, V. M. (2009). Infektsionnye oslozhneniya u onkologicheskikh bol'nykh. Praktycheskaia onkolohyia, 10 (3), 141–146.

Tretiak, N. M., Horiainova, N. V., Rybalska, A. P., Basova, O. V. (2007). Alhorytm terapii suprovodu pry hostrykh leikemiiakh. Onkoloyia, 9 (3), 258–261.

Dziublyk, Ia. O. (2010). Klinichni aspekty antybiotykorezystentnosti zbudnykiv nehospitalnykh infektsii dykhalnykh shliakhiv. Ukrainskyi pulmonolohichnyi zhurnal, 3, 53–56.

Kozhemiakyn, L. A. (2002). Mekhanizmy deystviya preparata Hlutoksim. Opportunisticheskie infektsii: problemy i perspektivy. Omsk: Omskaia medytsynskaia akademyia, 50–53.

Grinevich, Yu. A. (2003). Immunoterapiya v protivoopukholevom i protivoretsidivnom lechenii onkologicheskikh bol'nykh. Doctor, 4, 32–34.

Feshchenko, Iu. Y., Yshchuk, S. H., Matvyenko, Iu. A. (2012). Terapevticheskie vozmozhnosti innovatsionnogo immunomodulyatora v pul'monologii i ftiziatrii. Ukrainskyi pulmonolohichnyi zhurnal, 3, 50–54.

Iablonskyi, P. K., Aizykov, D. L., Balasaniants, H. S. (2011). Raschet potentsial'noy kliniko-ekonomicheskoy effektivnosti ispol'zovaniya preparata Hlutoksym® vo fizioterapii. Biulleten VSNTs SO RAMN, 2, 260–261.

Vakhnenko, A. V., Moisieieva, N. V. (2013). Zastosuvannia suchasnoho imunomoduliatora pry zahostrenni khronichnoho obstruktyvnoho zakhvoriuvannia lehen. Svit medytsyny ta biolohii, 4 (41), 14–19.

Mostovoi, Yu. M. (2013). Dosvid zastosuvannia imunomodeliuiuchoi terapii Hlutoksymom u khvorykh iz tiazhkym perebihom nehospitalnoi pnevmonii. Zdorov’ia Ukrainy, 23, 52–53.

Pertseva, T. O., Kireieva, T. V., Bielosludtseva, K. O. (2013). Kliniko–imunolohichne obgruntuvannia zastosuvannia imunomoduliatoriv u kompleksnii terapii tiazhkoi nehospitalnoi pnevmonii. Suchasni preparaty ta tekhnolohii, 9-10, 15–18.

Sokolova, H. B. et. al. (2002). Lechenye lekarstvenno- rezystentnoho tuberkuleza. Moscow, 15.

Standarty diahnostyky ta likuvannia onkolohichnykh khvorykh. Nakaz MOZ Ukrainy «Pro zatverdzhennia protokoliv nadannia medychnoi dopomohy za spetsialnistiu «Onkolohiia» vid 17.09.2007 r. No. 554 iz dopovnenniamy zghidno Nakazu MOZ Ukrainy No. 645 vid 30.07.2010 r. (2010). MOZ Ukrainy.

Nehospitalna ta nozokomialna (hospitalna) pnevmoniia u doroslykh osib: etiolohiia, patohenez, klasyfikatsiia, diahnostyka, antybakterialna terapiia. Nakaz MOZ Ukrainy «Pro zatverdzhennia klinichnykh protokoliv nadannia medychnoi dopomohy za spetsialnistiu «Pulmonolohiia» vid 19.03.2007 r. No. 128 (2007). Kyiv: Veles, 105–146.

Lanh, T. A., Sesyk, M. (2016). Kak opisyvat' statistiku v meditsine. Moscow: Praktycheskaia medytsyna, 480.

Smirnova, O. V., Manchuk, V. T. (2014). Features of immune cells in acute lymphoblastic leukemia. Medical Immunology, 15 (6), 577–584. doi: 10.15789/1563-0625-2013-6-577-584

Parakhonskyi, A. P. (2017). Narushenyia immunnoi systemy u bolnykh pnevmonyei y metody ikh korrektsyi. Sovremennye problemy allerholohii i immunolohyi. Available at: http://econf.rae.ru/article/534

Borysova, I., Pertseva, T., Kaplan, P. (2017). Pat. No. 1007559 UA. Sposib likuvannia pnevmonii na tli hostrykh leikoziv. MPK A61K 31/451, A61R 31/00, A61R37/00. No. 201601587; declareted: 22.02.16; published: 12.06.17, Bul. No. 11, 8.

Feshchenko, Iu. Y., Rekalova, E. M. (2013). Osobennosti sovremennoi immunomodulyruiushchei terapii. Astma ta alerhiia, 1, 6–12.

Vasyleva, S. N. (2007). Eksperymentalnoe obosnovanye ispolzovanyia Hlutoksyma® v kachestve sredstva soprovozhdenyia etyotropnoi terapii heneralzovannoho tuberkuleza. Saint Petersburg, 22.

Sinitsyn, M. V., Bohadelnykova, Y. V., Perelman, M. Y. (2010). Hlutoksym – 10 let vo ftyzyatryy (opyt prymenenyia pri lechenii tuberkuleza). Tuberkulez i bolezni lehkykh, 10, 3–9.




DOI: http://dx.doi.org/10.21303/2504-5679.2017.00430

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Inna Borisova

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)